Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Pharmacokinetics of MDV3100 1Neoplasm Metastasis 1Meningioma 1Memory Disorders 1Glioblastoma 1Cognitive Dysfunction 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 38Radiotherapy 17Filgrastim 14Surgical Procedures, Operative 11Irinotecan 11Carmustine 10Carboplatin 10Radiation 9O(6)-benzylguanine 9Magnetic Resonance Spectroscopy 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7Flucytosine 7sargramostim 6Radiotherapy, Intensity-Modulated 5Peripheral Blood Stem Cell Transplantation 5Etoposide 5Erlotinib Hydrochloride 5Bevacizumab 5vocimagene amiretrorepvec 4Vorinostat 4Thiotepa 4Melphalan 4Lenalidomide 4IL13-PE38 4Genetic Therapy 4Cyclophosphamide 4Chemotherapy, Adjuvant 4Busulfan 4lonafarnib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Astrocytoma × Pioglitazone × Clear all
NCT01151670 2018-08-01

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Wake Forest University Health Sciences

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Memory Disorders, Meningioma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡